placebo in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results COVACTA (Rosas), 2020 (REV) 0.98 [0.59; 1.62]
NCT04412772 (ARCHITECTS), 0 (REV) 5.56 [0.27; 114.80]
Rosas (REMDACTA), 2021 (REV) 1.05 [0.72; 1.54]
1.04 [0.77 ; 1.41 ] COVACTA (Rosas), 2020 (REV), NCT04412772 (ARCHITECTS), 0 (REV), Rosas (REMDACTA), 2021 (REV) 3 0% 1,099 moderate not evaluable death or transfer to ICUdetailed results BACC Bay Tocilizumab Trial, 2020 (REV) 1.03 [0.53; 2.00]
1.03 [0.53 ; 2.00 ] BACC Bay Tocilizumab Trial, 2020 (REV) 1 0% 242 NA not evaluable deathsdetailed results BACC Bay Tocilizumab Trial, 2020 (REV) 0.66 [0.18; 2.43]
COVACTA (Rosas), 2020 (REV) 0.86 [0.54; 1.36]
EMPACTA, 2020 (REV) 0.88 [0.42; 1.86]
NCT04412772 (ARCHITECTS), 0 (REV) 5.56 [0.27; 114.80]
Rosas (REMDACTA), 2021 (REV) 1.05 [0.72; 1.54]
0.96 [0.73 ; 1.25 ] BACC Bay Tocilizumab Trial, 2020 (REV), COVACTA (Rosas), 2020 (REV), EMPACTA, 2020 (REV), NCT04412772 (ARCHITECTS), 0 (REV), Rosas (REMDACTA), 2021 (REV) 5 0% 1,732 moderate not evaluable deaths (time to event analysis only)detailed results COVACTA (Rosas), 2020 (REV) 0.86 [0.54; 1.36]
Rosas (REMDACTA), 2021 (REV) 1.05 [0.72; 1.54]
0.97 [0.72 ; 1.30 ] COVACTA (Rosas), 2020 (REV), Rosas (REMDACTA), 2021 (REV) 2 0% 1,092 moderate not evaluable clinical deteriorationdetailed results BACC Bay Tocilizumab Trial, 2020 (REV) 0.90 [0.48; 1.70]
EMPACTA, 2020 (REV) 1.82 [1.09; 3.04]
1.31 [0.66 ; 2.61 ] BACC Bay Tocilizumab Trial, 2020 (REV), EMPACTA, 2020 (REV) 2 65% 242 moderate not evaluable clinical improvementdetailed results BACC Bay Tocilizumab Trial, 2020 (REV) 0.94 [0.71; 1.25]
COVACTA (Rosas), 2020 (REV) 0.84 [0.57; 1.24]
EMPACTA, 2020 (REV) 0.87 [0.68; 1.11]
0.89 [0.75 ; 1.05 ] BACC Bay Tocilizumab Trial, 2020 (REV), COVACTA (Rosas), 2020 (REV), EMPACTA, 2020 (REV) 3 0% 680 moderate not evaluable clinical improvement (28-day)detailed results COVACTA (Rosas), 2020 (REV) 0.84 [0.57; 1.24]
0.84 [0.57 ; 1.24 ] COVACTA (Rosas), 2020 (REV) 1 0% 438 NA not evaluable clinical improvement (time to event analysis only)detailed results EMPACTA, 2020 (REV) 0.87 [0.68; 1.11]
0.87 [0.68 ; 1.11 ] EMPACTA, 2020 (REV) 1 0% NA not evaluable death or ventilationdetailed results BACC Bay Tocilizumab Trial, 2020 (REV) 1.20 [0.55; 2.63]
EMPACTA, 2020 (REV) 1.79 [1.03; 3.11]
Rosas (REMDACTA), 2021 (REV) 1.02 [0.75; 1.39]
1.23 [0.86 ; 1.75 ] BACC Bay Tocilizumab Trial, 2020 (REV), EMPACTA, 2020 (REV), Rosas (REMDACTA), 2021 (REV) 3 33% 891 moderate not evaluable hospital dischargedetailed results EMPACTA, 2020 (REV) 0.86 [0.67; 1.11]
Rosas (REMDACTA), 2021 (REV) 1.03 [0.83; 1.27]
0.95 [0.80 ; 1.14 ] EMPACTA, 2020 (REV), Rosas (REMDACTA), 2021 (REV) 2 13% 649 moderate not evaluable mechanical ventilationdetailed results COVACTA (Rosas), 2020 (REV) 1.50 [0.88; 2.56]
1.50 [0.88 ; 2.56 ] COVACTA (Rosas), 2020 (REV) 1 0% 273 NA not evaluable ICU admissiondetailed results COVACTA (Rosas), 2020 (REV) 2.08 [1.07; 4.04]
2.08 [1.07 ; 4.04 ] COVACTA (Rosas), 2020 (REV) 1 0% 191 NA not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 (REV) 0.83 [0.40; 1.72]
COVACTA (Rosas), 2020 (REV) 1.23 [0.82; 1.85]
Rosas (REMDACTA), 2021 (REV) 1.20 [0.85; 1.71]
1.16 [0.90 ; 1.49 ] BACC Bay Tocilizumab Trial, 2020 (REV), COVACTA (Rosas), 2020 (REV), Rosas (REMDACTA), 2021 (REV) 3 0% 1,322 moderate not evaluable adverse eventsdetailed results COVACTA (Rosas), 2020 (REV) 1.16 [0.69; 1.94]
Rosas (REMDACTA), 2021 (REV) 0.76 [0.53; 1.09]
0.90 [0.60 ; 1.34 ] COVACTA (Rosas), 2020 (REV), Rosas (REMDACTA), 2021 (REV) 2 41% 1,080 moderate not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-21 17:58 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 650
- roots T: 650
